Blueshift Asset Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-8,269
Closed -$534K – 641
2026
Q1
$534K Buy
+8,269
New +$583K 0.16% 184
2025
Q3
– Sell
-11,021
Closed -$573K – 518
2025
Q2
$573K Buy
+11,021
New +$627K 0.18% 153
2021
Q4
– Sell
-19,197
Closed -$781K – 1010
2021
Q3
$781K Buy
19,197
+7,023
+58% +$294K 0.04% 476
2021
Q2
$553K Buy
12,174
+3,836
+46% +$170K 0.03% 528
2021
Q1
$348K Buy
+8,338
New +$381K 0.04% 591
2020
Q1
– Sell
-17,433
Closed -$309K – 404
2019
Q4
$309K Buy
+17,433
New +$302K 0.04% 594

Other funds holding HALO

Blueshift Asset Management's HALO Position: Q2 2026 in Review

Blueshift Asset Management sold out of Halozyme (HALO) in Q2 2026, closing a stake of 8,269 shares — an estimated $534K sold.

Blueshift Asset Management first reported a position in HALO in Q4 2019 and held it in 6 quarters. The position peaked at $781K in Q3 2021. 674 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Blueshift Asset Management reported no remaining Halozyme position as of Q2 2026 after selling out during the quarter.
  • Blueshift Asset Management sold 8,269 Halozyme shares in Q2 2026, an estimated $534K.
  • Blueshift Asset Management first reported a position in Halozyme in Q4 2019 and held it in 6 quarters.
  • Blueshift Asset Management's Halozyme position peaked at $781K in Q3 2021.
  • 674 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Blueshift Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.